Lee's Pharmaceutical Holdings (950) Stock Overview
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
950 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lee's Pharmaceutical Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.68 |
| 52 Week High | HK$2.70 |
| 52 Week Low | HK$1.15 |
| Beta | 0.56 |
| 1 Month Change | -8.20% |
| 3 Month Change | -30.86% |
| 1 Year Change | 20.00% |
| 3 Year Change | -7.69% |
| 5 Year Change | -66.06% |
| Change since IPO | 223.08% |
Recent News & Updates
Recent updates
Lee's Pharmaceutical Holdings Limited's (HKG:950) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 18
We Think Lee's Pharmaceutical Holdings' (HKG:950) Profit Is Only A Baseline For What They Can Achieve
Sep 03Lee's Pharmaceutical Holdings (HKG:950) Is Due To Pay A Dividend Of HK$0.022
Aug 28Lee's Pharmaceutical Holdings Limited's (HKG:950) 26% Share Price Surge Not Quite Adding Up
Jul 30Lee's Pharmaceutical Holdings (HKG:950) Will Pay A Larger Dividend Than Last Year At HK$0.025
Mar 31What Lee's Pharmaceutical Holdings Limited's (HKG:950) P/E Is Not Telling You
Mar 20Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem
Sep 04There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price
Aug 07Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01
May 21Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking
Dec 20Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01
May 21Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01
Apr 02Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01
Aug 29Shareholder Returns
| 950 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.2% | 0.7% | -1.7% |
| 1Y | 20.0% | 67.7% | 29.4% |
Return vs Industry: 950 underperformed the Hong Kong Pharmaceuticals industry which returned 67.7% over the past year.
Return vs Market: 950 underperformed the Hong Kong Market which returned 29.4% over the past year.
Price Volatility
| 950 volatility | |
|---|---|
| 950 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.3% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 950 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 950's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,036 | n/a | www.leespharm.com |
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments.
Lee's Pharmaceutical Holdings Limited Fundamentals Summary
| 950 fundamental statistics | |
|---|---|
| Market cap | HK$989.24m |
| Earnings (TTM) | HK$97.81m |
| Revenue (TTM) | HK$1.44b |
Is 950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 950 income statement (TTM) | |
|---|---|
| Revenue | HK$1.44b |
| Cost of Revenue | HK$673.63m |
| Gross Profit | HK$762.81m |
| Other Expenses | HK$665.01m |
| Earnings | HK$97.81m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 53.10% |
| Net Profit Margin | 6.81% |
| Debt/Equity Ratio | 12.6% |
How did 950 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:00 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lee's Pharmaceutical Holdings Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chu Wang | Citigroup Inc |
| Jun Zhou Li | Everbright Securities Co. Ltd. |
| Yue-Kwong Lui | Jefferies LLC |